Specialty pharmaceutical firm Akorn (AKRX) finishes the day up over 10% after its Q3 easily beats estimates. Revenue jumped 69% Y/Y on higher sales and the continued growth of its injectable and ophthalmic products launched in 2010. Gross margin rose to 60% due to a favorable product mix, price increases and more efficient plant utilization.
Specialty pharmaceutical firm Akorn (AKRX) finishes the day up over 10% after its Q3 easily...
From other sites
at CNBC.com (Mar 4, 2015)
at CNBC.com (Jul 15, 2014)
at CNBC.com (Jun 23, 2014)
at CNBC.com (Jan 23, 2014)
at CNBC.com (Aug 27, 2013)
ETF Screener: Search and filter by asset class, strategy, theme, performance, yield, and much more
ETF Performance: View ETF performance across key asset classes and investing themes
ETF Investing Guide: Learn how to build and manage a well-diversified, low cost ETF portfolio
ETF Selector: An explanation of how to select and use ETFs